News Search Results
Jul 09, 2025, 11:40 ET Process Instrumentation Market Size to Reach USD 27.93 billion by 2031 with a 5.8% CAGR, Experiences Growth with Rising Industrial Automation Across the Globe | The Insight Partners
consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact
More news about: The Insight Partners
Jul 09, 2025, 11:20 ET Metal Processing Machines Market Size Worth USD 42.29 Billion by 2031 at a 5.3% CAGR, Experiences Increasing Importance of Metal Processing Machines in Construction Sector | The Insight Partners
consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact
More news about: The Insight Partners
Jul 09, 2025, 11:00 ET Electric Vehicle Market Size to Surpass USD 2492.5 Billion by 2031, Experiences Growth Due to Low Ownership Cost Compared to ICE Vehicles | The Insight Partners
consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact
More news about: The Insight Partners
Jul 09, 2025, 08:32 ET GenScript Biotech Earns EcoVadis Silver Medal, Ranking in Top 15% Globally for Sustainability
to addressing climate change. Looking ahead, GenScript remains dedicated to its mission of "Making People and Nature Healthier through Biotechnology," and will continue integrating sustainability into its global business strategy. Through technological innovation and international collaboration,
More news about: GenScript Biotech Corporation
Jul 09, 2025, 08:31 ET MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated Dose
July 9, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced dosing of the first patient in the 48 mg, multiple ascending dose (MAD)
More news about: MetaVia Inc.
Jul 09, 2025, 08:30 ET ABS Bio Appoints Ehab Alramahy as President & CEO
"3BC") portfolio company and a leader in biospecimen sourcing, cell culture services, and biorepository solutions for the global pharmaceutical and biotechnology industry, today announced the appointment of Ehab Alramahy as President and Chief Executive Officer. Company founder
More news about: 3 Boomerang Capital; ABS Bio
Jul 09, 2025, 08:30 ET Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
modulator for the treatment of cystic fibrosis (https://ibn.fm/HCgSh). A global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions, Vertex reported
More news about: NetworkNewsWire
Jul 09, 2025, 08:00 ET Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) will issue
More news about: Anixa Biosciences, Inc.
Jul 09, 2025, 07:00 ET Genomenon and UCB Partner to Advance Thymidine Kinase 2 Deficiency Awareness and Diagnosis
ClinVar, the widely used public archive of reports on human variations classified by disease and drug responses, hosted by the National Center for Biotechnology Information (NCBI). TK2d is a rare, autosomal, recessive mitochondrial disease primarily characterized by progressive and severe myopathy.
More news about: Genomenon
Jul 09, 2025, 07:00 ET Transposon Receives Investment from the Alzheimer's Drug Discovery Foundation to Support Advancement of TPN-101 for the Treatment of Alzheimer's Disease
DIEGO, July 9, 2025 /PRNewswire/ -- Transposon Therapeutics, a biotechnology company focused on developing novel, orally administered therapies for the treatment of neurodegenerative and aging-related diseases, including
More news about: Transposon Therapeutics
Jul 09, 2025, 06:45 ET FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Jul 09, 2025, 03:00 ET Actithera Raises $75.5M in Oversubscribed Series A Financing to Redefine Precision Radioligand Therapy
co-investors to translate scientific discoveries into commercial success. M Ventures focuses on investing along the two extensive investment areas Biotechnology and Technology covering the areas of Healthcare drug development, Life Science tools, Electronics, and Frontier Technology & Sustainability.
More news about: Actithera
Jul 08, 2025, 23:27 ET First Patient Dosed in Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418
2025 /PRNewswire/ -- Duality Biotherapeutics' ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced the first patient has been dosed in the Phase 1 portion of a Phase 1/2 clinical
More news about: Duality Biotherapeutics
Jul 08, 2025, 23:14 ET First Patient Dosed in Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418
2025 /PRNewswire/ -- Duality Biotherapeutics' ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced the first patient has been dosed in the Phase 1 portion of a Phase 1/2 clinical
More news about: Duality Biotherapeutics
Jul 08, 2025, 19:00 ET U.S. FDA Grants Orphan Drug Designation to Adcentrx Therapeutics' ADRX-0405 STEAP1 ADC for Gastric Cancer
Adcentrx Therapeutics ("Adcentrx"), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and other life-threatening diseases, today announced that the U.S.
More news about: Adcentrx Therapeutics
Jul 08, 2025, 16:20 ET Centivax Raises Oversubscribed $45 Million Series A Led by Future Ventures to Advance Universal Flu Vaccine into Clinic and Expand Universal Immunity Portfolio
FRANCISCO, Calif., July 8, 2025 /PRNewswire/ -- Centivax, Inc., a biotechnology company engineering vaccines and therapies for durable, universal protection against highly diverse targets, today announced the close of an oversubscribed
More news about: Centivax
Jul 08, 2025, 16:05 ET Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025
July 8, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology,
More news about: Tyra Biosciences
Jul 08, 2025, 13:08 ET Rubin and Rudman Partners Joseph Bodoff and Rion Vaughan Named to 2025 Lawdragon 500 Leading Global Bankruptcy & Restructuring Lawyers
Rubin and Rudman serves national and international companies, including large public companies and closely held businesses; real estate developers; biotechnology, pharmaceutical and medical device makers; regulated industries, public entities and municipalities; insurance companies and their insureds; educational
More news about: Rubin and Rudman
Jul 08, 2025, 12:00 ET Biotia Partners with Leading Korean Pharmaceutical Company to Advance Infectious Disease Diagnostics in Remote Regions -- Including in Space
QUEENS, N.Y., July 8, 2025 /PRNewswire/ -- Biotia, a biotechnology company pioneering the development of novel infectious disease diagnostics, today announced its selection as an awardee in the Humans in Space
More news about: Biotia, Inc.
Jul 08, 2025, 11:30 ET Colorectal Cancer Treatment Market Size is Projected to Reach USD 24.77 Billion, with a Robust 3.2% CAGR till 2031, Rising Prevalence of Cancer Boosts | The Insight Partners
consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact
More news about: The Insight Partners
Jul 08, 2025, 11:15 ET Fluorine-18 Market Size Projected to USD 2.54 Billion by 2031 with 4.7% CAGR, Experiences Growth with Rising Prevalence of Cancer | The Insight Partners
consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact
More news about: The Insight Partners
Jul 08, 2025, 11:10 ET FTRE Investors Have the Opportunity to Lead the Fortrea Holdings Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
from buy to hold. Among other things, the Jefferies Report cited perceived weaknesses in the Company's business model as a CRO amid pressure on biotechnology funding and suggested that the cost savings Fortrea expects to achieve by exiting the TSAs are "not as material as [o]ne [m]ight think," stating
More news about: Faruqi & Faruqi, LLP
Jul 08, 2025, 10:45 ET Dental Bone Graft and Substitutes Market to Hit USD 1,098.48 million by 2031 | Global Outlook & Forecast at 7.21% CAGR | The Insight Partners
consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact
More news about: The Insight Partners
Jul 08, 2025, 09:00 ET Cizzle Bio Submits NIH Grant Proposal with Premier Research Institutions to Advance Biomarker Blood Test for Lung Cancer
SAN ANTONIO, July 8, 2025 /PRNewswire/ -- Cizzle Bio, Inc., a biotechnology company pioneering innovative biomarker blood tests for early detection of lung and gastric cancers, has submitted a grant application to the National
More news about: Cizzle Bio
Jul 08, 2025, 09:00 ET Sensorium Therapeutics Receives FDA IND Clearance for SNTX-2643, a First-in-Class, Rapid-Acting Anxiolytic
About Sensorium Sensorium Therapeutics is a clinical–stage biotechnology company developing brain and mental health treatments that are derived from nature, mechanistically driven, clinically precise, and designed to
More news about: Sensorium Therapeutics, Inc